By the nature of their unknown pathogenicity, variants of unknown significance (VUS) should not inform clinical decisions for genetic carrier testing; nevertheless, VUS are increasingly returned to patients. We argue that the benefits of returning VUS to patients are outweighed by the potential for individual and health-care system-level harm.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hunter, D. J. Uncertainty in the era of precision medicine. N. Engl. J. Med. 375, 711–713 (2016).
Makhnoon, S. et al. Experiences of patients seeking to participate in variant of uncertain significance reclassification research. J. Community Genet. https://doi.org/10.1007/s12687-018-0375-3 (2018).
Welsh, J. L. et al. Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes. Ann. Surg. Oncol. 24, 3067–3072 (2017).
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–423 (2015).
Wynn, J. et al. Clinical providers’ experiences with returning results from genomic sequencing: an interview study. BMC Med. Genomics 11, 45 (2018).
Elwyn, G., Cochran, N. & Pignone, M. Shared decision making — the importance of diagnosing preferences. JAMA Intern. Med. 177, 1239–1240 (2017).
Knight, F. H. Risk, Uncertainty and Profit (Hart, Schaffner & Marx, NY, 1921).
Regier, D. A. et al. Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment. CMAJ 187, E190–E197 (2015).
The authors thank C. McCabe for his valuable feedback on the development of this comment. They acknowledge support from the Canadian Institutes of Health Research (PCG-155555) and from Genome British Columbia’s Societal Issues Grant (SOC001). The Canadian Centre for Applied Research in Cancer Control (ARCC) is funded by Canadian Cancer Society Grant no. 2015-703549.
D.A.R. has received travel support from Illumina to attend conferences in Boston, USA, and Barcelona, Spain. S.P. and S.S. declare no competing interests.
About this article
Cite this article
Pollard, S., Sun, S. & Regier, D.A. Balancing uncertainty with patient autonomy in precision medicine. Nat Rev Genet 20, 251–252 (2019). https://doi.org/10.1038/s41576-019-0111-9
European Journal of Human Genetics (2022)
The Patient - Patient-Centered Outcomes Research (2021)
Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges
Journal of Community Genetics (2019)